Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 20/20 | 0.65 |
| ▸ | CXCR2 | P25025 | 20/20 | 0.65 |
| ▸ | CCR7 | P32248 | 4/20 | 0.65 |
| ▸ | CCR6 | P51684 | 3/20 | 0.55 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.55 |
| ▸ | CCR4 | P51679 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13208142 | 0.88 | CXCR1 (0.70) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL13207269 | 0.86 | CXCR2 (0.48) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL13207247 | 0.85 | CXCR2 (0.46) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL13207244 | 0.85 | CXCR2 (0.48) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL13440408 | 0.85 | CXCR1 (0.67) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL13947514 | 0.85 | CXCR1 (0.67) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL13207253 | 0.84 | CXCR2 (0.57) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL13207004 | 0.83 | CXCR1 (0.77) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL13207007 | 0.82 | CXCR2 (0.77) | CXCR1CXCR2CCR7 | |
| SCHEMBL12262779 | 0.82 | CXCR1 (0.93) | CXCR1CXCR2CCR7CCR6CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1551818-B1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | CXCR1 4/4885CXCR2 6/4885CCR7 16/4885 |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | CXCR1 1/4885CXCR2 6/4885CCR7 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.